Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the "Company") dated 22 July 2024 (the "Announcement"). Unless otherwise defined, capitalized terms in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, on 22 July 2024, the Company received the written resignation from Mr. Li that he shall resign as the chairperson and executive director of the 9th session of the Board and the chairman of the Strategic Development and Investment Committee of the Board of the Company, effective from 22 July 2024. Mr. Li stated in the written resignation that he was resigning for "personal reasons" and no further elaborations were provided. However, Mr. Li confirmed in the written resignation that he had no disagreement with the Board and there were no matters relating to his resignation that were needed to be brought to the attention of the shareholders of the Company.

As of the date of this announcement, save as disclosed in the Announcement, the Company has not been provided with any details pertaining to Mr. Li's resignation that would confirm the specific reasons for his resignation.

The Board of

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 8 August 2024

As at the date of this announcement, the Board comprises Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.